ArticleBMC research notes2026
Utility of urinary podocalyxin levels in patients with and without type 2 diabetic nephropathy and its correlation with renal function.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposePodocalyxin is a urinary protein that may serve as a potential indicator for the early detection of diabetic nephropathy. The objectives of this study were to assess urinary podocalyxin levels in patients with and without type 2 diabetic nephropathy and to determine its correlation with renal function. MATERIALS AND
methodsThis cross-sectional analytical study was conducted at a tertiary care teaching hospital in south India for 18 months. Study subjects were divided into four groups: non-diabetics, diabetics without albuminuria, diabetics with microalbuminuria, and diabetics with macroalbuminuria. Urinary albumin was detected by the dipstick method in a spot urine sample for all study subjects. Urinary albumin was quantified by nephelometry. The enzyme-linked immunosorbent assay (ELISA) technique estimated urinary podocalyxin levels in all groups.
resultsUrinary podocalyxin levels were elevated in diabetic subjects compared to the control group. There was a positive correlation between urinary podocalyxin and urine albumin-creatinine ratio (UACR) in diabetic study subjects. No correlation was found between urinary podocalyxin and estimated glomerular filtration rate (eGFR). Urinary podocalyxin showed a sensitivity of 85% and specificity of 64% (at a cut-off value of 275.56 ng/mL) in estimating albuminuria in diabetic subjects. Urinary podocalyxin showed a sensitivity of 89% and specificity of 78% (at a cut-off value of 273.38 ng/mL) in estimating eGFR in diabetic subjects.
conclusionUrinary podocalyxin levels were elevated in patients with type 2 diabetic nephropathy. It was positively correlated with the urine albumin-creatinine ratio in diabetic subjects. However, there was no correlation with the estimated glomerular filtration rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.